PKD phosphorylation and COP9/Signalosome modulate intracellular Spry2 protein stability

  1. Martínez, Natalia
  2. Gragera, Teresa
  3. de Lucas, María Pilar
  4. Cámara, Ana Belén
  5. Ballester, Alicia
  6. Anta, Berta
  7. Fernández-Medarde, Alberto
  8. López-Briones, Tania
  9. Ortega, Judith
  10. Peña-Jiménez, Daniel
  11. Barbáchano, Antonio
  12. Montero-Calle, Ana
  13. Cordero, Víctor
  14. Barderas, Rodrigo
  15. Iglesias, Teresa
  16. Yunta, Mónica
  17. Oliva, José Luís
  18. Muñoz, Alberto
  19. Santos, Eugenio
  20. Zarich, Natasha
  21. Rojas-Cabañeros, José M.
Revista:
Oncogenesis

ISSN: 2157-9024

Año de publicación: 2023

Volumen: 12

Número: 1

Tipo: Artículo

DOI: 10.1038/S41389-023-00465-3 GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Oncogenesis

Objetivos de desarrollo sostenible

Referencias bibliográficas

  • Cabrita MA, Christofori G. Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis. 2008;11:53–62.
  • de Maximy AA, Nakatake Y, Moncada S, Itoh N, Thiery JP, Bellusci S. Cloning and expression pattern of a mouse homologue of drosophila sprouty in the mouse embryo. Mech Dev. 1999;81:213–6.
  • Tefft JD, Lee M, Smith S, Leinwand M, Zhao J, Bringas P Jr., et al. Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesis. Curr Biol. 1999;9:219–22.
  • Masoumi-Moghaddam S, Amini A, Morris DL. The developing story of Sprouty and cancer. Cancer Metastasis Rev. 2014;33:695–720.
  • Sanchez A, Setien F, Martinez N, Oliva JL, Herranz M, Fraga MF, et al. Epigenetic inactivation of the ERK inhibitor Spry2 in B-cell diffuse lymphomas. Oncogene. 2008;27:4969–72.
  • Barbachano A, Fernandez-Barral A, Pereira F, Segura MF, Ordonez-Moran P, Carrillo-de Santa Pau E, et al. SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150. Oncogene. 2016;35:2991–3003.
  • Holgren C, Dougherty U, Edwin F, Cerasi D, Taylor I, Fichera A, et al. Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. Oncogene. 2010;29:5241–53.
  • Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, et al. Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. Eur J Cancer. 2011;47:1946–54.
  • Bloethner S, Chen B, Hemminki K, Muller-Berghaus J, Ugurel S, Schadendorf D, et al. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis. 2005;26:1224–32.
  • Swat A, Dolado I, Rojas JM, Nebreda AR. Cell density-dependent inhibition of epidermal growth factor receptor signaling by p38alpha mitogen-activated protein kinase via Sprouty2 downregulation. Mol Cell Biol. 2009;29:3332–43.
  • Haglund K, Schmidt MHH, Wong ES, Guy GR, Dikic I. Sprouty2 acts at the Cbl/CIN85 interface to inhibit epidermal growth factor receptor downregulation. EMBO Rep. 2005;6:635–41.
  • Okur MN, Ooi J, Fong CW, Martinez N, Garcia-Dominguez C, Rojas JM, et al. Intersectin 1 enhances Cbl ubiquitylation of epidermal growth factor receptor through regulation of Sprouty2-Cbl interaction. Mol Cell Biol. 2012;32:817–25.
  • Aranda S, Alvarez M, Turro S, Laguna A, de la Luna S. Sprouty2-mediated inhibition of fibroblast growth factor signaling is modulated by the protein kinase DYRK1A. Mol Cell Biol. 2008;28:5899–911.
  • Ferron SR, Pozo N, Laguna A, Aranda S, Porlan E, Moreno M, et al. Regulated segregation of kinase Dyrk1A during asymmetric neural stem cell division is critical for EGFR-mediated biased signaling. Cell Stem Cell. 2010;7:367–79.
  • DaSilva J, Xu L, Kim HJ, Miller WT, Bar-Sagi D. Regulation of sprouty stability by Mnk1-dependent phosphorylation. Mol Cell Biol. 2006;26:1898–907.
  • Kim HJ, Taylor LJ, Bar-Sagi D. Spatial regulation of EGFR signaling by Sprouty2. Curr Biol. 2007;17:455–61.
  • Dubiel D, Rockel B, Naumann M, Dubiel W. Diversity of COP9 signalosome structures and functional consequences. FEBS Lett. 2015;589:2507–13.
  • Nishikawa K, Toker A, Johannes FJ, Songyang Z, Cantley LC. Determination of the specific substrate sequence motifs of protein kinase C isozymes. J Biol Chem. 1997;272:952–60.
  • Iglesias T, Waldron RT, Rozengurt E. Identification of in vivo phosphorylation sites required for protein kinase D activation. J Biol Chem. 1998;273:27662–7.
  • Uhle S, Medalia O, Waldron R, Dumdey R, Henklein P, Bech-Otschir D, et al. Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. EMBO J. 2003;22:1302–12.
  • Wei N, Serino G, Deng XW. The COP9 signalosome: more than a protease. Trends Biochem Sci. 2008;33:592–600.
  • Guy GR, Jackson RA, Yusoff P, Chow SY. Sprouty proteins: modified modulators, matchmakers or missing links? J Endocrinol. 2009;203:191–202.
  • Hicks KC, Patel TB. Sprouty2 protein regulates hypoxia-inducible factor-α (HIFα) protein levels and transcription of HIFα-responsive genes. J Biol Chem. 2016;291:16787–801.
  • Saini M, Verma A, Mathew SJ. SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma. Cell Death Dis. 2018;9:237.
  • Edwin F, Anderson K, Patel TB. HECT domain-containing E3 ubiquitin ligase Nedd4 interacts with and ubiquitinates Sprouty2. J Biol Chem. 2010;285:255–64.
  • Fong CW, Leong HF, Wong ES, Lim J, Yusoff P, Guy GR. Tyrosine phosphorylation of Sprouty2 enhances its interaction with c-Cbl and is crucial for its function. J Biol Chem. 2003;278:33456–64.
  • Nadeau RJ, Toher JL, Yang X, Kovalenko D, Friesel R. Regulation of Sprouty2 stability by mammalian Seven-in-Absentia homolog 2. J Cell Biochem 2007;100:151–60.
  • Anderson K, Nordquist KA, Gao X, Hicks KC, Zhai B, Gygi SP, et al. Regulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteins. J Biol Chem. 2011;286:42027–36.
  • Chow SY, Yu CY, Guy GR. Sprouty2 interacts with protein kinase C delta and disrupts phosphorylation of protein kinase D1. J Biol Chem. 2009;284:19623–36.
  • Lingaraju GM, Bunker RD, Cavadini S, Hess D, Hassiepen U, Renatus M, et al. Crystal structure of the human COP9 signalosome. Nature. 2014;512:161–5.
  • Zarich N, Anta B, Fernandez-Medarde A, Ballester A, de Lucas MP, Camara AB, et al. The CSN3 subunit of the COP9 signalosome interacts with the HD region of Sos1 regulating stability of this GEF protein. Oncogenesis. 2019;8:2.
  • Li P, Xie L, Gu Y, Li J, Xie J. Roles of multifunctional COP9 signalosome complex in cell fate and implications for drug discovery. J Cell Physiol. 2017;232:1246–53.
  • Martinez N, Garcia-Dominguez CA, Domingo B, Oliva JL, Zarich N, Sanchez A, et al. Sprouty2 binds Grb2 at two different proline-rich regions, and the mechanism of ERK inhibition is independent of this interaction. Cell Signal. 2007;19:2277–85.
  • Matthews SA, Iglesias T, Rozengurt E, Cantrell D. Spatial and temporal regulation of protein kinase D (PKD). EMBO J. 2000;19:2935–45.